The reporter learned from the National Health Commission that in recent years, the level of cancer screening and treatment in China has continued to improve, and the rising trend of cancer incidence rate and mortality has been initially curbed, especially the incidence and mortality of Chinese traditional high incidence upper gastrointestinal tumors have significantly decreased.
At present, China has initially established a four level cancer prevention and control network at the national, provincial, municipal, and county levels. A nationwide population tumor registration system has been established, with tumor registration points covering 98.6% of districts and counties nationwide, providing scientific basis for cancer prevention and control. China has formulated and released a series of cancer screening, early diagnosis and early treatment programs for esophageal cancer, gastric cancer, lung cancer, colorectal cancer, cervical cancer, breast cancer and other cancers. The annual coverage of cancer screening and early diagnosis and treatment exceeds 80 million people, and the coverage rate of women's "two cancers" screening in districts and counties reaches 98%. The expected early diagnosis rate of key cancer types in key areas exceeds 55%. The overall 5-year cancer survival rate in China has increased from 40.5% in 2015 to 43.7% in 2022.
Fan Daiming, an academician of the CAE Member, said: "From the perspective of human constitution, tumors have heredity. Roughly 15% to 30% of tumors are caused by changes in their own genomes and genes brought from the fetus. From the perspective of external factors that cause tumors, it is infectious, such as hepatitis B virus infection, hepatitis virus infection; and HPV caused cervical cancer, this HPV is infectious."
Nowadays, the public is paying more and more attention to physical examinations, and some people even undergo specialized examinations for cancer. Among these examinations, the most widely known is tumor marker testing. According to experts, currently in China, tumor biomarker testing includes protein, enzyme, hormone, and genetic markers. If these markers are found to be elevated, especially significantly elevated, there may be a close association with cancer, but it cannot be equated with cancer.
Nie Yongzhan, Chairman of the Tumor Markers Committee of the Chinese Anti Cancer Association, said, "If other markers are only slightly higher than normal, we can consult professional doctors or go to other hospitals for another review. If it is still elevated, we can dynamically observe it, but we must find a doctor and cooperate with other examinations such as ultrasound and CT to determine. This is beneficial for these patients
Experts explain that pulmonary nodules are not equivalent to lung cancer, and the vast majority are benign. When a pulmonary nodule is first detected on a chest CT scan, do not panic. Regular follow-up examinations should be conducted according to the doctor's advice to observe changes in the pulmonary nodule.
Although most lung nodules are benign and do not require clinical treatment, in recent years, there has been a significant increase in lung cancer patients aged 40-50. According to experts, due to the unclear early symptoms of lung cancer, 70% to 80% of patients are diagnosed in the middle to late stages, thus missing the best treatment opportunity. The survival rate of lung cancer patients is closely related to cancer staging, and the earlier they are detected, the higher their long-term survival rate.

